In the effort to characterize, detect, and treat dementia, the concept of mild cognitive impairment (MCI) has acquired considerable credibility during the past decade. Beginning with Krai's description of benign senescent forgetfulness in 1962, 1 clinical criteria of increasing specificity and validity have been proposed for identification of individuals functioning in the uncertain area between normal cognitive aging and dementia. In comparison to normally aging adults, those with clinical MCI, and particularly those with the amnestic subtype of MCI, are more functionally impaired, more likely to show Alzheimer's-like neuropathological changes and imaging abnormalities, and more likely to convert to Alzheimer's disease or other dementias.
In the effort to characterize, detect, and treat dementia, the concept of mild cognitive impairment (MCI) has acquired considerable credibility during the past decade. Beginning with Krai's description of benign senescent forgetfulness in 1962, 1 clinical criteria of increasing specificity and validity have been proposed for identification of individuals functioning in the uncertain area between normal cognitive aging and dementia. In comparison to normally aging adults, those with clinical MCI, and particularly those with the amnestic subtype of MCI, are more functionally impaired, more likely to show Alzheimer's-like neuropathological changes and imaging abnormalities, and more likely to convert to Alzheimer's disease or other dementias.
This issue of CNS Spectrums addresses the nature and significance of MCI from three distinct viewpoints. The three articles included here should provide the reader with a solid basis for understanding the nature of MCI, detecting its clinical presence, characterizing its subtype, planning comprehensive treatment, appreciating the value of psychiatric appraisal of associated noncognitive symptoms, and evaluating the significance of ongoing MCI research.
The review by Ron Petersen, MD, PhD, and Selamawit Negash, PhD, provide an authoritative overview of the evolution and recognition of MCI as a clinical entity. The authors explain the historical and revised diagnostic criteria for MCI and its subtypes and describe an algorithmic approach to clinical evaluation and management. An overview of research on MCI discusses epidemiologic findings, the significance of several biomarkers, and the neuropathologic findings reported from several autopsy studies. The section on treatment reviews the most significant pharmacologic treatment studies and also describes what has been learned about the preventive value of lifestyle factors including cognitive stimulation and nutritional factors. The clinical approach to MCI described in this article by Petersen and colleagues is organized, practical, and grounded in the best evidence available.
The next article deepens the discussion of clinical assessment by describing a state-ofthe-art approach to neuropsychological assessment of MCI patients. Aaron P. Nelson, PhD, and Margaret G. O'Connor, PhD, masterfully walk the reader through the process of evaluation, beginning with the patient's complaint and the collection of elucidating data from an informant. They explore the relative usefulness of population norms versus intra-individual comparisons for assessing MCl's presence and severity. They describe the "hypothesis testing" assessment approach and characterize the testing instruments of greatest value in detecting and subtyping MCI, considering its differential diagnosis, and gauging the magnitude of impairment in specific cognitive domains. Readers without advanced neuropsychological training will find the discussion of testing domains and instruments interesting reading and practical reference material.
The final MCI article reports findings from a small study of MCI patients viewed through a different lens, one focused on concurrent mood and behavioral symptoms rather than cognitive ones. Although MCI has been defined solely on the basis of impairments in memory or other cognitive functions, the high prevalence of noncognitive mood and behavioral symptoms in MCI patients has been noted in several large population-based or clinical studies. Assessment with the Neuropsychiatric Inventory (NPI) has found noncognitive symptoms in up to 75% of MCI subjects, 2 and these noncognitive symptoms are often the ones that lead to psychiatric consultation. Depression, nighttime behaviors, irritability, agitation, apathy, and anxiety are the NPI symptoms most frequently detected in MCI patients. Depression may be difficult to rec-Introduction ognize in a cognitively impaired patient but its presence impairs function and undermines quality of life. The presence of NPI symptoms in MCI patients, as discussed in this report by James M. Ellison, MD, MPH, and colleagues, may have both clinical and prognostic significance in work with MCI patients. In this preliminary study, a high rate of NPI symptoms was found in MCI patients evaluated by a psychiatric hospital's outpatient memory clinic. Within the limitations of the study's methodology, the presence of apathy appeared more closely linked with amnestic than non-amnestic MCI, while the presence of nighttime behaviors appeared more closely linked with non-amnestic MCI. Depression was very common in both MCI subgroups.
The characterization and investigation of MCI has had far-reaching effects on our understanding of normal and pathological cognitive aging. Readers should emerge with a richer appreciation of MCl's definition, construct validity, clinical significance, and management. In addition, these articles point toward some of the expected refinements in diagnostic and treatment approaches that will shape our care of aging and elderly patients in the future. CNS
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CNS Spectrums' Web portal is now better than ever -a one-stop source providing the following -'•< integrated bi-ivices based on input from you... our readers: GEODON is contraindicated in patients with a known history of QT prolongation, recent acute myocardial infarction, or uncompensated heart failure, and should not be used with other QT-prolonging drugs. GEODON has a greater capacity to prolong the QTC interval than several antipsychotics. In some drugs, QT prolongation has been associated with torsade de pointes, a potentially fatal arrhythmia. In many cases this would lead to the conclusion that other drugs should be tried first.
As with all antipsychotic medications, a rare and potentially fatal condition known as neuroleptic malignant syndrome (NMS) has been reported with GEODON. NMS can cause hyperpyrexia, muscle rigidity, diaphoresis, tachycardia, irregular pulse or blood pressure, cardiac dysrhythmia, and altered mental status. If signs and symptoms appear, immediate discontinuation, treatment, and monitoring are recommended.
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Prescribing should be consistent with the need to minimize tardive dyskinesia (TD), a potentially irreversible dose-and durationdependent syndrome. If signs and symptoms appear, discontinuation should be considered since TD may remit partially or completely.
Hyperglycemia-related adverse events, sometimes serious, have been reported in patients treated with atypical antipsychotics.
There have been few reports of hyperglycemia or diabetes in patients treated with GEODON, and it is not known if GEODON is associated with these events. Patients treated with an atypical antipsychotic should be monitored for symptoms of hyperglycemia.
Precautions include the risk of rash, orthostatic hypotension, and seizures.
The most common adverse events associated with GEODON in bipolar mania were somnolence, extrapyramidal symptoms, dizziness, akathisia, and abnormal vision.
In short-term schizophrenia trials, the most commonly observed adverse events associated with GEODON at an incidence of s5% and at least twice the rate of placebo were somnolence and respiratory tract infection.
In short-term schizophrenia clinical trials, 10% of GEODONtreated patients experienced a weight gain of 2:7% of body weight vs 4% for placebo.
BRIEF SUMMARY. See package insert for full prescribing information. IncreasedMortalnVinEldertyPatientswittiDementia-RelatedPsvchosisiEldeflypatientswithdementia-relatedpsychosistreatedwith atypical antipsychotic drugs are at an increased risk ol death compared to placebo. Analyses of seventeen placebo controlled trials (modal duration of10weeks| in these patients revealed anskofdealh in the drug-treated patients ofbetween1.6to1.7times that seen in placebo-treated patients. Over the course of a typical 10 week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared toarate of about2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either canfiovascular(e.||, heart failure, sudden death) or infectious (e.g., pneumonia) in nature. GEODON (ziprasidone) is not approved for the treatment of patients with Dementia-Delated Psychosis. Although the prevalence of TD appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patientsare likely to developTD. Ifsigns and symptoms of TD appear inapatient on GEODON, drug discontinuation should be considered. Hyperglycemia and Diabetes Melllu&tt/tmgtycemia-reteteti adverse events, sometimes serious, have been reported in patients treated wrlh atypical antipsychotics. There have been few reports of hyperglycemia or diabetes in patients treated with GEOOON, and it is not known if GEODON is associated with these events. Patients treated with an atypical antipsychotic should be monitored for symptoms of hyperglycemia. PRECAUTIONS-General: RasjL In premarketing trials, about 5% of GEODON patients developed rash and/or urticaria, with discontinuation oftreatment in aboutone-sixth of these cases. The occurrence of rash was dose related,although the finding might also be explained bylonger exposure in higher-dose patients. Several patients wrth rash had signsand symptoms of associated systemic illness, e.g., elevated WBCs. Most patients improved promptly upon treatment with antihistamines or steroids and/or upon discontinuation of GEODON, and all patients were reported to recover completely. Upon appearance of rash tor which an alternative etiology cannot be identified, GEODON should be discontinued. Orthostatic Hypotension: GEODON may induce orthostatic hypotension associated with dizziness, tachycardia, and, in some patients, syncope, especially during the initial dose-titration period, probably reflecting its a,-adrenergic antagonist properties. Syncope was reported in 0.6% of GEODON patients. GEODON should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease or conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). Seizures: In clinical trials, seizures occurred in 0.4% of GEODON patients. There were confounding factors that may have contributed to seizures in many of these cases. As wrth other antipsychotic drugs, GEODON should be used cautiously in patients witii a history of seizures orwith conditions that potentially lowerthe seizure threshold, e.g., Alzheimer's dementia. Conditions that lower the seizure threshold may be more prevalent in a population of 65 years or older. Dvsphaoia: Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer's dementia, and GEODON and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia. Neitherclinical studies norepidemiologic studies conductedtodate have shown an association between chronic administration of thisclass of drugs and tumorigenesis in humans; the available evidence is considered too limited to be conclusive at this time. Potential for Cognitive andMntnrlmnairment Somnolence wasa commonly reported adverse event in GEODON patients. Inthe 4-and 6-week placebo^controlled trials, somnolence was reported in 14% of GEODON patients vs 7% of placebo patients. Somnolence led to discontinuation in 0.3% of patients in short-term clinical trials. Since GEODON has the potential to impair judgment, thinking, or motor skills, patients should be cautioned about performing activities requiring mental alertness, such as operating a motor vehicle (including automobiles) or operating hazardous machinery until theyare reasonably certainthatGEODONtherapydoesnotaffectthemadversely.PrjarjIsni: One case of priapism was reported in the premarketing database. Body Temperature Regulation: Although not reported with GEODON in premarketing trials, disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Suicide: The possibility of a suicide attempt is inherent in psychotic illness and close supervision of high-risk patients should accompany drug therapy. GEODON prescriptions should be written for the smallest quantity of capsules consistent with good patient management to reduce overdose risk. Use in Patients with Concomitant Illness: Clinical experience with GFODON in natients with certain concomitant systemic illnesses is limited. GEODON has not been evaluated or used to any appreciable extent in patients witharecent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were excluded from premarketing clinical studies. Because of the risk of QT, prolongation and orthostatic hypotension with GEODON, caution should be observed in cardiac palierts{seeQTProlongationandBiskotSuddenOeathm WARNINGS and Orthostatic Hypotension in PRECAUTIONS). Information forPatients:To ensure safe and effective use of GEODON, the information and instructions in the PatientMrnationSectmtfuM be dscussed with patients. Laboratory Tests: Patients being considered for GEODON treatment who are at risk of significant electrolyte disturbances should have baseline serum potassium and magnesium measurements. Low serum potassium and magnesium should be repleted before treatment. Patients who are started on diuretics during GEODON therapy need periodic monitoring o1 serum potassium and magnesium. Discontinue GEODON in patients who are found to have persistentQTDmeasurements>500msec(see WARNINGS). Droo/nterac«ons:(1)GEODONshould not be used with anydrugthatprolongs the QT interval. (2) Given the primary CNS effects of GEODON, caution should be used when it is taken in combination with other centrally acting drugs. (3) Because of its potential for inducing hypotension, GEODON may enhance the effects of certain antihypertensive agents. In vitro studies revealed little potential for GEODON to interfere with the metabolism of drugs cleared primarily by CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, and little potential for drug interactions wfth GEODON due to displacement. GEODON 40 mg bid administered concomitantly with »»m450 mg bid for 7 days did notatfectthe steadystate level or renal clearance of lithium. GEODON 20 mg bid did not affect the pharmacokinetics of concomitantly administered oral cor*ace(rties,ethiny!estradiol (0.03 mg)andlevonorgestrel(0.15mg). Consistent with in vitro results.astudy in normal healthy volunteers showed that GEODON did not alter the metabolism of dextrometwrphan, a CYP2D6 model substrate, to its major metabolite, dextrorphan. There was no statistically significant change in the urinary dextromethorphan/dextrorphan ratio. Carclnogenesls, Mutagenesis, ImpairmentotFertility:Lifetime carcinogenicity studies were conducted with GEODON in Long Evans rats and CD-1 mice. In male mice, there was no increase in incidence of tumors relative to controls. In female mice there were dose-related increases inthe incidences of pituitary gland adenoma and carcinoma, and mammary gland adenocarcinoma at all doses tested. Increases in serum prolactin were observed in a 1 -month dietary study in female, but not male, mice. GEOOON had no effect on serum prolactin in rats in a 5-week dietary study at the doses that were used inthe carcinogenicity study. The relevance forhuman risk of the findings of prolactin-mediated endocrine tumors in rodents is unknown (see Hvperprolactinemia). Mutagenesis: There was a reproducible mutagenic response in the Ames assay in one strain of S. typhiimirium in the absence of metabolic activation. Positive results were obtained in both the in vitro mammalian cell gene mutation assay and the in vitro chromosomal aberration assay in human lymphocytes. Impairment of Fertility: GEODON increased time to copulation in Sprague-Dawley rats in two fertility and early embryonic development studies at doses of 1Oto 160 mg/kg/day (0.5 to 8 times the MRHD of 200 mg/day on a mg/m ! basis). Fertility rate was reduced at 160 mg/kg/day (8 times the MRHD on a mg/m ! basis). There was no effectonfertility at 40 mg/kg/day (2 times the MRHDonamg/nf basis). The fertility of female rats was reduced. ftBj/BmvPregnancyCategoryC'There are no adequate and well-controlled studies in pregnant women. GEODON should be used during pregnancy only if the potential benefit justifies the potential riskto the fetus. £atara/»<0e)/re/y:TheeffectofGEODON on labor and delivery in humans is unknown. Nursing Mowers: It is not known whether, and if so in what amount, GEODON or its metabolites are excreted in human milk. It is recommended that women receiving GEODON should not breast feed. Pediatric Use The safety and effectiveness of GEODON in pediatric patients have not been established. Geriatric Use: Of the approximately 4500 patients treated with GEODON in clinical studies, 2.4% (109) were 65 years ofage or over. In general, there was no indication of any different tolerability for GEODON or ol reduced clearance of GEODON in the elderly compared to younger adults. Nevertheless, the presence of multiple factors that might increase the pharmacodynamic response to GEODON, or cause poorer tolerance or orthostasis, should lead to consideration of a lower starting dose, stowertitration, and careful monitoring duringthe initial dosing period for some elderly patients. ADVERSE REACTIONS-/W»«seH(io7/>||s Observed in Short-term, Placebo-Controlled mate: Tile following findings are based on the short-term placebo-controlled premarketing trials for schizophrenia (a pool of two 6-week, and two 4-week fixed-dose trials) and bipolar mania (apod of two 3-week flexible-dose trials) in which GEODON was administered in doses ranging from 10 to 200 mg/day. Adverse Events Associated with Discontinuation: Schizophrenia: Approximately4.1%(29/702)ofGEODON-treated patients inshort-term, placebo-controlled studies discontinued treatment due to an adverse event, compared with about 2.2% (6/273) on placebo. The most common event associated with dropout was rash, including 7 dropoutsfor rash among GEODON patients (1%) compared to no placebo patients (see PRECAUTIONS). Bipolar Mania: Approximately 6.5% (187279) of GEODON-treated patients in short-term, placebo-controlled studies discontinued treatment due to an adverse event, compared with about 3.7% (5/136) on placebo. The most common events associated with dropout in the GEODON-treated patients were akathisia, anxiety, depression, dizziness, dystonia, rash andvomrting,with2dropoutsforeach of these eventsamong GEODON patients (1 %) compared to one placebo patient each for dystonia and rash (1 %) and no placebo patients for the remaining adverse events. Adverse Events at an Incidence > 5% and at Least Twice Hie Rale ol Placebo: The most commonly observed adverse events associated with GEODON in schizophrenia trials were somnolence (14%) and respiratory tract infection (8%). The most commonly observed adverse events associated with the use of GEODON in bipolar mania trials were somnolence (31 %), extrapyramidal symptoms (31 %), dizziness (16%), akathisia (10%), abnormal vision (6%), asthenia (6%), and vomiting (5%). The following list enumerates the treatment-emergent adverse events that occurred during acute therapy, including only those events that occurred in 2% of GEODON patients and at a greater incidence than in placebo. Schizophrenia: Bndv as a Whole-asthenia, accidental injury, chest pain. Cardiovascular-tachycardia. Digestive-nausea, constipation, dyspepsia, diarrhea, dry mouth, anorexia. Nervous.-extrapyramidal symptoms, somnolence, akathisia, dizziness. Respiratory-respiratory tract infection, rhinitis, cough increased. Skin and Appendages-rash, fungal dermatitis. Special Senses-abnormal vision. Bipolar Mania: Bndv as a Whole-headache, asthenia, accidental injury. Cardiovascular-hypertension. Digestive-nausea, diarrhea, dry mouth, vomiting, increased salivation.tonoue edema, dvsphaoia. Musculoskeletal-myalgia. Nervoussomnolence, extrapyramidal symptoms, dizziness, akathisia, anxiety, hypesthesia, speech disorder. Respiratory-pharyngitis, dyspnea. Skin and Appendages-fungal dermatitis. Special Senses-abnormal vision. Dose Dependency: An analysis for dose response in the schizophrenia trials revealed an apparent relation of adverse event to dose forthe following: asthenia, postural hypotension, anorexia, dry mouth, increased salivation, arthralgia, anxiety, dizziness, dystonia, hypertonia, somnolence, tremor, rhinitis, rash, and abnormal vision. ExtrapyramidalSymptoms(EPS):lt£ incidence of reported EPS forGEODON patients inthe short-term, placebo-controlled schizophrenia trials was 14% vs 8% for placebo. Objectively collected data from those trials on the Simpson-Angus Rating Scale and the Barnes Akathisia Scale did not generally showa difference between GEODON and placebo. Vital Sign Changes.GEODON is associated with orthostatic hypotension (see PRECAUTIONS). Weight Gain: In short-term schizophrenia trials, the proportions of patients meeting a weight gain criterion of £7% of body weight were compared, revealing a statistically significantfy greater incidence of weight gain forGEODON patients (10%) vs placebo patients (4%). A median weight gain of 0.5 kg was observed in GEODON patients vs 0.0 kg in placebo patients. Weight gain was reported as an adverse event in 0.4% of both GEODON and placebo patients. During long-term therapy with GEODON, a categorization of patients at baselineonthe basis of body mass index (BMI)showed the greatest mean weight gainand the highestincidence of clinically significant weight gain (>7% of body weight) in patients with a low BMI (<23) compared to normal (23-27) or overweight (>27) patients. There was a mean weight gain of 1.4 kg for patients with a "low" baseline BMI, 0.0 kg for patients wrth a "normal" BMI, and a 13 kg mean weight loss for patients with a "high" BMI. ECG Changes: GEODOU is associated with an increase in the QT( interval (see WARNINGS). In schizophrenia trials, GEODON was associated with a mean increase in heart rate of 1.4 beats per minute compared to a 0.2 beats per minute decrease among placebo patients. Other Adverse Events Observed During the Prenorketlng Evaluation olGEODOH: Frequent adverse events are those occurring in at least 1/100 patients; infrequent adverse events are those occurring in 1/100 to 1/1000 natients: rare events are those occurrinn in fewer than 1/1000 patients. Schizophrenia: Body as a Whole-frmuentabdominal pain, flu svndrome.tever. accidental tall, face edema, chills, photosensitivitv reaction, flank pain, hypothermia, motorvehicle accident. Cardiovascular System-Frajuenttachycardia, hypertension, postural hypotension; Infrequent bradycardia, angina pectoris, atrial fibrillation; Rare: firstdegree AV block, bundle branch block, phlebitis, pulmonary embolus, cardiomegaly, cerebral infarct, cerebrovascular accident, deep thrombophlebitis, myocarditis, thrombophlebitis. Digestive System-Frequent anorexia, vomiting: Infrequent rectal hemorrhage, dysphagia, tongue edema; toe.gum hemorrhage, jaundice, fecal impaction, gamma glutamyl transpeptidase increased, hematemesis, cholestatic jaundice, hepatitis, hepatomegaly, leukoplakia of mouth, fatty liver deposit, melena. Endicjini-flare.hypothyroidism, rivperthvroidism. thvroiriitis. Hemicanri I vmphatin System-Infrequent anemia, ecchvmosis. leukocvtnsis. leukopenia. eosinophilia. tymphadenopathy; Rare:thrombocytopenia, hypochromic anemia, lymphocytosis, monocytosis, basophilia, lymphedema, polycythemia, thromboevthemia. Metabolic and Nutritional Disorders-Mamentthirst transaminase increased, peripheral edema, hyperolvcemia, creatine phosphokinase increased, alkaline phosphatase increased, hypercholesteremia, dehydration, lactic dehydrogenase increased, albuminuria, hypokalemia; toe:BUN increased, creatinine increased, hyperlipemia, hypocholesteremia, hyperkalemia, hypochloremia, hypoglycemia, hyponatremia, hypoproteinemia, glucose tolerance decreased, gout, nyperchioremia, hyperuricemia, hypocalcemia, hypoglycemic reaction, hypomagnesemia, ketosis, respiratory alkalosis. Musculoskeletal System-Frequent: myalgia; /nfreougnf: tenosvnovitis: tofi.mvopathv. Nervnus System-Frequent agitation, extrapyramidal syndrome, tremor, dvstonia. hvoertonia. dyskinesia, hostility, twitching, paresthesia, confusion, vertigo, hypokinesia, hyperkinesia, abnormal gait, oculogyric crisis, hypesthesia, ataxia, amnesia, cogwheel rigidity, delirium, hypotonia, akinesia,dysarthna, wrthdrawal syndrome, buccoglossal syndrome, cltoreoathetosis, diplopia, incoordination, neuropathy; /nfrggumtparalysis; Rare: myoclonus, nystagmus, torticollis, circumoral paresthesia, opisthotonos, reflexes increased, trismus. Respiratory System-Frequentttosmea; //jfrgm/eflf:pneumonia.epistaxis: Rare, hemoptysis, larvngismus. Skin and Appendages-Infrequent: maculopapular rash, urticaria, alopecia, eczema, exfoliative dermatitis, contact dermatitis, vesiculobullous rash. Special Senses-Frequent:iuuw\ dermatitis; Infrequent conjunctivitis, dry eyes, tinnitus, blepharitis, cataract, photophobia: Bare/eve hemorrhane.yisiialfielddefert.keratitis.keratoconiunctiyitis.lJrogenital System-Mrer/«;/)t impotence, abnormal ejaculation, amenorrhea, liematuria, menorrhagia, female lactation, polyuria, urinary retention, metrorrhagia, male sexual dysfunction, anorgasmia, glycosuria; Rare: gynecomastia, vaginal hemorrhage, nocturia, oliguria, female sexual dysfunction, uterine hemorrhage. Adverse Finding Observed in Trials of IntramuscularGEODON: In these studies, the most commonly observed adverse events associated with the use of intramuscular GEODON (25%) and observed at a rate on intramuscular GEODON (in the higher dose groups) at least twice that of the lowest intramuscular GEODON group were headache (13%), nausea (12%), and somnolence (20%). Adverse Events at an Incidence >1% in Short-Term Fixed-Dose Intramuscular Trials: The following list enumerates the treatment-emergent adverse events that occurred in 21 % of GEODON patients (in the higher dose groups) and at least twice that of the lowest intramuscular GEODON group. Body asaWhole-headache, injection site pain, asthenia, abdominal pain.flu syndrome, back pain. Cardiovascular-postural hypotension, hypertension, bradycardia, vasodilation. Digestive-nausea, rectal hemorrhage, diarrhea, vomiting, dyspepsia, anorexia, constipation, tooth disorder, dry mouth. Nervous-dizziness, anxiety, insomnia, somnolence.akathisia, agitation, extrapyramidal syndrome, hypertonia, cogwheel rigidity, paresthesia, personality disorder, psychosis, speech disorder. Respiratory-rhinitis. Skin and Appendagesfurunculosis, sweating. Umgenitai-dysmenorrhea, priapism. DRUG ABUSE AND DEPENDENCE-Controlled Substance Class: GEODON is notacontrolled substance. OVERDOSAGE-In premarketing trials in over 5400 patients, accidental or intentional overdosage of GEODON was documented iniOpatients. All patients survived without sequelae. In the patient taking the largest confirmed amount(3240 mg), the only symptoms reported were minimal sedation, slurring of speech, and transitory hypertension (BP200/95).
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